BridgeBio CEO trust sells 10,000 shares at up to $69.64
BridgeBio Pharma’s CEO reported Rule 10b5-1 plan share sales while retaining significant direct and trust-held equity positions.
Rhea-AI Filing Summary
BridgeBio Pharma, Inc. (BBIO) reported that Chief Executive Officer and director Neil Kumar had trusts associated with him sell a total of 10,000 shares of common stock on September 17, 2026, in open-market transactions under a Rule 10b5-1 sales plan adopted on May 13, 2026.
The Kumar Haldea Family Irrevocable Trust sold 8,721 shares at a weighted average price between $68.52 and $69.40 per share and 1,279 shares between $69.525 and $69.64 per share. Neil Kumar reports large remaining indirect holdings, including 3,568,447 shares via a revocable trust and 750,000 shares via the NK 2026 GRAT, plus 243,327 shares held directly, while disclaiming beneficial ownership of certain trust-held shares except for any pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Net Seller: 10,000 shares
Net Sell
5 txns
Insider
Kumar Neil
Role
Chief Executive Officer
Sold
10,000 shs ($691K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2, F3 | 8,721 | $69.0136 | $602K |
| Sale | Common Stock F1, F4, F3 | 1,279 | $69.5696 | $89K |
| holding | Common Stock F3 | -- | -- | -- |
| holding | Common Stock F5 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 495,686 shares (Indirect, By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.);
Common Stock — 3,568,447 shares (Indirect, By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.);
Common Stock — 750,000 shares (Indirect, By NK 2026 GRAT);
Common Stock — 243,327 shares (Direct)
Footnotes (5)
- F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026.
- F2. Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
- F4. Represents the weighted average sale price of the shares sold from $69.525 to $69.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F5. These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.
Key Figures
Shares sold (first transaction): 8,721 shares
Shares sold (second transaction): 1,279 shares
Total shares sold: 10,000 shares
+5 more
8 metrics
Shares sold (first transaction)
8,721 shares
Common stock sold on September 17, 2026 by Kumar Haldea Family Irrevocable Trust
Shares sold (second transaction)
1,279 shares
Common stock sold on September 17, 2026 by Kumar Haldea Family Irrevocable Trust
Total shares sold
10,000 shares
Aggregate of reported sale transactions on September 17, 2026
Price range (8,721-share sale)
$68.52–$69.40 per share
Weighted average sale price range disclosed in footnote F2
Price range (1,279-share sale)
$69.525–$69.64 per share
Weighted average sale price range disclosed in footnote F4
Indirect holdings via revocable trust
3,568,447 shares
Common stock held indirectly by Kumar Haldea Revocable Trust after transactions
Indirect holdings via NK 2026 GRAT
750,000 shares
Common stock held indirectly by NK 2026 GRAT after transactions
Direct holdings
243,327 shares
Common stock held directly by Neil Kumar after transactions
Key Terms
Rule 10b5-1 sales plan, weighted average sale price, beneficial ownership, pecuniary interest, +1 more
5 terms
Rule 10b5-1 sales plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 sales plan"
weighted average sale price financial
"Represents the weighted average sale price of the shares sold"
beneficial ownership regulatory
"disclaims beneficial ownership of these shares except to the extent"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of his pecuniary interest therein"
grantor retained annuity trust financial
"NK 2026 GRAT, a grantor retained annuity trust"
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BridgeBio Pharma (BBIO) disclose about Neil Kumar’s recent stock transactions?
BridgeBio Pharma reported that CEO Neil Kumar had trusts associated with him sell 10,000 shares of common stock on September 17, 2026 in open-market transactions under a Rule 10b5-1 sales plan adopted on May 13, 2026.
Were Neil Kumar’s BBIO stock sales made under a Rule 10b5-1 plan?
Yes. A footnote states that the transactions were effected pursuant to a Rule 10b5-1 sales plan adopted by Neil Kumar on May 13, 2026, and the filing’s Rule 10b5-1 checkbox is affirmed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
